Roberta Sanfilippo

5PUBLICATIONS
50CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersAboriginal and Torres Strait Islander marketing
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Jan 17, 2024
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo

|Sep 12, 2023
Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment.

Roberta Sanfilippo, Marta Sbaraglia, Chiara Fabbroni

|Dec 08, 2022
Preoperative Neutrophil-to-Lymphocyte Ratio and a New Inflammatory Biomarkers Prognostic Index for Primary Retroperitoneal Sarcomas: Retrospective Monocentric Study.

Marco Fiore, Silva Ljevar, Sandro Pasquali

|Oct 05, 2022
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.

Bruno Vincenzi, Andrea Napolitano, Alessandro Comandone

Pageof 1

Frequent Collaborators

3 joint publications

Paolo Giovanni Casali

2 joint publications

Jean-Yves Blay

2 joint publications

Javier Martín-Broto

2 joint publications

Sandro Pasquali